Correction to "Effect of Bromocriptine-QR (a Quick-Release Formulation of Bromocriptine Mesylate) on Major Adverse Cardiovascular Events in Type 2 Diabetes Subjects" [J Am Heart Assoc., 1, (2012), e002279] 10.1161/JAHA.112.002279;Effect of bromocriptine-QR (a quick-release formulation of bromocriptine mesylate) on major adverse cardiovascular events in type 2 diabetes subjects

Journal of the American Heart Association

Volumn 1, Issue 5, 2012, Pages

  Michael Gaziano, J ^a   Cincotta, Anthony H ^b   Vinik, Aaron ^c   Blonde, Lawrence ^d   Bohannon, Nancy ^e   Scranton, Richard ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b VeroScience LLC   (United States)

^c Strelitz Diabetes Center   (United States)

^d OCHSNER MEDICAL CENTER   (United States)

^e St Luke's Hospital   (United States)

Author keywords

Bromocriptine; Circadian rhythm; Cycloset; Diabetes mellitus type 2; Infarction

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BROMOCRIPTINE MESILATE; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FIBRIC ACID DERIVATIVE; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOOP DIURETIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; THIAZIDE DIURETIC AGENT; BROMOCRIPTINE; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT;

ADULT; ANGINA PECTORIS; AORTA DISSECTION; AORTA RUPTURE; ARTERY EMBOLISM; ARTICLE; BLOOD PRESSURE; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE DURATION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG WITHDRAWAL; FEMALE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; HYPERGLYCEMIA; LIFESTYLE MODIFICATION; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MULTICENTER STUDY (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; SUDDEN DEATH; UNSPECIFIED SIDE EFFECT; UNSTABLE ANGINA PECTORIS; AGED; CIRCADIAN RHYTHM; CONTROLLED CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; DRUG POTENTIATION; INFARCTION; INTENTION TO TREAT ANALYSIS; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; TREATMENT OUTCOME;

BROMOCRIPTINE; CIRCADIAN RHYTHM; CYCLOSET; DIABETES MELLITUS TYPE 2; INFARCTION;

AGED; BROMOCRIPTINE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DOPAMINE AGONISTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INTENTION TO TREAT ANALYSIS; MALE; MIDDLE AGED; RECEPTORS, DOPAMINE D2; RISK FACTORS; TREATMENT OUTCOME;

EID: 84877038797     PISSN: None     EISSN: 20479980     Source Type: Journal    
DOI: 10.1161/JAHA.115.001991     Document Type: Erratum

References (46)

1. Cincotta AH, Meier AH, Cincotta M Jr. Bromocriptine improves glycaemic control and serum lipid profile in obese type 2 diabetic subjects: a new approach in the treatment of diabetes. Expert Opin Investig Drugs. 1999;8:1683-1707.
2. Scranton R, Cincotta A. Bromocriptine - unique formulation of a dopamine agonist for the treatment of type 2 diabetes. Expert Opin Pharmacother. 2010;11:269-279.
3. Cycloset [package insert]. Tiverton, RI: VeroScience LLC; 2010.
4. Scranton RE, Gaziano JM, Rutty D, Ezrokhi M, Cincotta A. A randomized, double-blind, placebo-controlled trial to assess safety and tolerability during treatment of type 2 diabetes with usual diabetes therapy and either Cycloset or placebo. BMC Endocr Disord. 2007;7:3.
5. Gaziano JM, Cincotta AH, O'Connor CM, Ezrokhi M, Rutty D, Ma ZJ, Scranton RE. Randomized clinical trial of quick-release bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes. Diabetes Care. 2010;33:1503-1508.
6. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2004;27(suppl 1):S5-S10.
7. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care. 2004;27(suppl 1):S15-S35.
8. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG, Friedewald WT. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545-2559.
9. Patel A, MacMahon S, Chalmers J, Neal B, Woodward M, Billot L, Harrap S, Poulter N, Marre M, Cooper M, Glasziou P, Grobbee DE, Hamet P, Heller S, Liu LS, Mancia G, Mogensen CE, Pan CY, Rodgers A, Williams B; ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007;370:829-840.
10. Cincotta AH. Hypothalamic role in insulin resistance and insulin resistance syndrome. In: Hansen B, Shafrir E, eds. Frontiers in Animal Diabetes Research. London: Taylor and Francis; 2002:271-312.
11. Liang Y, Cincotta AH. Increased responsiveness to the hyperglycemic, hyperglucagonemic and hyperinsulinemic effects of circulating norepinephrine in ob/ob mice. Int J Obes Relat Metab Disord. 2001;25:698-704.
12. Arner P. Catecholamine-induced lipolysis in obesity. Int J Obes Relat Metab Disord. 1999;23(suppl 1):10-13.
13. Cincotta AH, Luo S, Zhang Y, Liang Y, Bina KG, Jetton TL, Scislowski PW. Chronic infusion of norepinephrine into the VMH of normal rats induces the obese glucose-intolerant state. Am J Physiol Regul Integr Comp Physiol. 2000;278:R435-R444.
14. Cusi K. The role of adipose tissue and lipotoxicity in the pathogenesis of type 2 diabetes. Curr Diab Rep. 2010;10:306-315.
15. Cherrington AD. Control of glucose uptake and release by the liver in vivo. Diabetes. 1999;48:1198-1214.
16. Dicostanzo CA, Dardevet DP, Neal DW, Lautz M, Allen E, Snead W, Cherrington AD. Role of the hepatic sympathetic nerves in the regulation of net hepatic glucose uptake and the mediation of the portal glucose signal. Am J Physiol. 2006;290:E9-E16.
17. Nielsen MF, Caumo A, Chandramouli V, Schumann WC, Cobelli C, Landau BR, Vilstrup H, Rizza RA, Schmitz O. Impaired basal glucose effectiveness but unaltered fasting glucose release and gluconeogenesis during short-term hypercortisolemia in healthy subjects. Am J Physiol Endocrinol Metab. 2004;286: E102-E110.
18. Goldstein RE, Rossetti L, Palmer BA, Liu R, Massillon D, Scott M, Neal D, Williams P, Peeler B, Cherrington AD. Effects of fasting and glucocorticoids on hepatic gluconeogenesis assessed using two independent methods in vivo. Am J Physiol Endocrinol Metab. 2002;283:E946-E957.
19. Grassi G, Bombelli M, Seravalle G, Dell'Oro R, Quarti-Trevano F. Diurnal blood pressure variation and sympathetic activity. Hypertens Res. 2010;33:381-385.
20. Tsuji H, Larson MG, Venditti FJ Jr, Manders ES, Evans JC, Feldman CL, Levy D. Impact of reduced heart rate variability on risk factors for cardiac events: the Framingham Heart Study. Circulation. 1992;94:2850-2855.
21. Kannel WB, Kanel C, Paffenbarger RS, Cupples LA. Heart rate and cardiovascular mortality: the Framingham Study. Am Heart J. 1987;113:1489-1494.
22. Huikuri HV, Jokinen V, Syvänne M, Nieminen MS, Airaksinen KE, Ikäheimo MJ, Koistinen JM, Kauma H, Kesäniemi AY, Majahalme S, Niemelä KO, Frick MH. Heart rate variability and progression of coronary atherosclerosis. Arterioscler Thromb Vasc Biol. 1999;19:1979-1985.
23. Vinik AI, Maser RE, Ziegler D. Autonomic imbalance: prophet of doom or scope for hope? Diabet Med. 2011;28:643-651.
24. Yu S-M, Tsai S-Y, Guh J-H, Lo F-H, Teng C-M, Ou J-T. Mechanisms of catecholamine-induced proliferation of vascular smooth muscle cells. Circulation. 1996;94:547-554.
25. Kukerja RS, Datta BN, Chakra-Vari RN. Catecholamine-induced aggravation of aortic and coronary atherosclerosis in monkeys. Atherosclerosis. 1981;40:291-298.
26. Beere PA, Glagov S, Zarins CK. Retarding effect of lowered heart rate on coronary atherosclerosis. Science. 1984;226:180-182.
27. Ramchandra R, Barrett CJ, Malpas SC. Nitric oxide and sympathetic nerve activity in the control of blood pressure. Clin Exp Pharmacol Physiol. 2005;32:440-446.
28. Palatini P. Sympathetic overactivity in hypertension: a risk factor for cardiovascular disease. Curr Hypertens Rep. 2001;3(suppl 1):S3-S9.
29. Fagerholm V, Haaparanta M, Scheinin M. Alpha2-adrenoceptor regulation of blood glucose homeostasis. Basic Clin Pharmacol Toxicol. 2011;108:365-370.
30. Bernstein IM, Damron D, Schonberg AL, Shapiro R. The relationship of plasma volume, sympathetic tone, and proinflammatory cytokines in young healthy nonpregnant women. Reprod Sci. 2009;16:980-985.
31. Palatini P. Elevated heart rate as a predictor of increased cardiovascular morbidity. J Hypertens Suppl. 1999;17:S3-S10.
32. Schulz E, Gori T, Munzel T. Oxidative stress and endothelial dysfunction in hypertension. Hypertens Res. 2011;34:665-673.
33. Gayen JR, Zhang K, Ramachandra Rao SP, Mahata M, Chen Y, Kim HS, Naviaux RK, Sharma K, Mahata SK, O'Connor DT. Role of reactive oxygen species in hyperadrenergic hypertension: biochemical, physiological, and pharmacological evidence from targeted ablation of the chromogranin a (Chga) gene. Circ Cardiovasc Genet. 2010;3:414-425.
34. Rahman S, Rahman T, Ismail A, Rashid ARA. Diabetes-associated macrovasculopathy: pathophysiology and pathogenesis. Diabetes Obes Metab. 2007;9:767-780.
35. Perin PC, Maule S, Quadri R. Sympathetic nervous system, diabetes, and hypertension. Clin Exp Hypertens. 2001;23:45-55.
36. Masuo K, Rakugi H, Ogihara T, Esler MD, Lambert GW. Cardiovascular and renal complications of type 2 diabetes in obesity: role of sympathetic nerve activity and insulin resistance. Curr Diabetes Rev. 2010;6:58-67.
37. Conde SV, Nunes da Silva T, Gonzalez C, Mota Carmo M, Monteiro EC, Guarino MP. Chronic caffeine intake decreases circulating catecholamines and prevents diet-induced insulin resistance and hypertension in rats. Br J Nutr. 2012;107:86-95.
38. Lambert EA, Lambert GW. Stress and its role in sympathetic nervous system activation in hypertension and the metabolic syndrome. Curr Hypertens Rep. 2011;13:244-248.
39. Lambert GW, Straznicky NE, Lambert EA, Dixon JB, Schlaich MP. Sympathetic nervous activation in obesity and the metabolic syndrome-causes, consequences and therapeutic implications. Pharmacol Ther. 2010;126:159-172.
40. Ezrokhi M, Trubitsyna Y, Luo S, Cincotta AH. Timed dopamine agonist treatment ameliorates both vascular nitrosative/oxidative stress pathology and aortic stiffness in arteriosclerotic, hypertensive SHR rats (Abstract). Diabetes. 2010;59(suppl 1):A67.
41. Whaley-Connell A, McCullough PA, Sowers JR. The role of oxidative stress in the metabolic syndrome. Rev Cardiovasc Med. 2011;12:21-29.
42. Cincotta AH, Gaziano JM, Ezrokhi M, Scranton RE. Cycloset (quick-release bromocriptine mesylate), a novel centrally acting treatment for type 2 diabetes (Abstract). Diabetologia. 2008;51(suppl 1):S22.
43. Scranton RE, Farwell W, Ezrokhi M, Gaziano JM, Cincotta AH. Quick release bromocriptine (Cycloset®) a novel treatment for type 2 diabetes also demonstrates improvements in blood pressure (Abstract). Can J Diabetes. 2009;3:235.
44. Sowers JR. Dopaminergic control of circadian norepinephrine levels in patients with essential hypertension. J Clin Endocrinol Metab. 1981;53:1133-1137.
45. Sowers JR, Golub MS, Berger ME, Whitfield LA. Dopaminergic modulation of pressor and hormonal responses in essential hypertension. Hypertension. 1982;4:424-430.
46. Kolloch R, Kobayashi K, DeQuattro V. Dopaminergic control of sympathetic tone and blood pressure: evidence on primary hypertension. Hypertension. 1980;2:390-394.